Arcus Biosciences was a clinical-stage biopharmaceutical company headquartered in Hayward, California, focused on developing novel cancer immunotherapies and inflammatory disease treatments. The company was founded in 2015 by Terry McGuire and Jennifer D. Johnson, building on research from Stanford University.
Overview
Mermaid diagram (expand to render)
Arcus Biosciences operated with a mission to create differentiated cancer immunotherapies by targeting key pathways in the tumor microenvironment. The company established strategic partnerships with major pharmaceutical companies including Gilead Sciences and Pfizer, leveraging its proprietary technology platform to develop next-generation immunotherapies["@arcusa"].
The company's approach focused on:
- Immune checkpoint inhibition: Targeting novel pathways beyond PD-1
- Adenosine receptor antagonism: Modulating the immunosuppressive adenosine pathway
- CD73 inhibition: Blocking adenosine generation in the tumor microenvironment
- TIGIT blockade: Preventing tumor immune evasion
Funding
- IPO: 2018 (NASDAQ: RCUS)
- Market Cap: ~$2B (2026)
Company History and Development
Founding and Early Growth (2015-2020)
Arcus was founded in 2015 with technology licensed from Stanford University, focusing on adenosine receptor biology. The company raised over $400 million in multiple financing rounds before its IPO in 2018.
Gilead Partnership and Expansion (2016-2023)
In 2016, Arcus entered into a strategic collaboration with Gilead Sciences, granting Gilead exclusive rights to Arcus's clinical-stage programs. This partnership was expanded multiple times, including:
- 2017: Expanded partnership to include additional programs
- 2020: Gilead invested $375 million in Arcus (20% equity)
- 2023: Announced intent to acquire Arcus for $14.6 billion[@gilead]
Acquisition by Gilead Sciences
- Announcement: November 2023
- Closing: March 2024
- Deal Value: Approximately $14.6 billion USD ($58 per share)
- Strategic Rationale: Strengthened Gilead's oncology portfolio with Arcus's innovative immunotherapy pipeline
Pipeline and Programs
Clinical Programs
| Drug Candidate | Target | Indication | Stage |
|---------------|--------|------------|-------|
| Domvanalimab | TIGIT | NSCLC, gastric cancer | Phase 3[@domvanalimab] |
| Zimberelimab | PD-1 | Multiple cancers | Phase 2/3 |
| Etrumadenant | A2a/A2b adenosine receptor | Renal cell carcinoma | Phase 2 |
| Quemliclustat | CD73 | Solid tumors | Phase 1/2 |
| Mupadolimab | CD73 | Solid tumors | Phase 1/2 |
Research Programs
- AB309: Next-generation anti-TIGIT antibody with enhanced effector function
- AB821: Novel immunomodulatory agent targeting innate immunity
- AB308: Immuno-oncology candidate with novel mechanism
- AB680: Hydrolysis-stabile CD73 inhibitor
Adenosine Pathway Inhibition
The adenosine pathway is a key immunosuppressive mechanism in the tumor microenvironment. Tumors produce adenosine through CD73 and CD39 enzymes, which then activate A2a and A2b receptors on immune cells, suppressing anti-tumor immunity[@adenosine].
Arcus's adenosine receptor antagonists (etrumadenant) block this immunosuppressive signaling, potentially restoring immune cell function.
TIGIT Targeting
TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an immune checkpoint expressed on T cells and NK cells. Domvanalimab is a next-generation anti-TIGIT antibody that prevents TIGIT from binding to its ligands (CD155, CD112), thereby enhancing anti-tumor immune responses[@tigit2020].
Clinical Development Highlights
Domvanalimab (Anti-TIGIT)
- Phase 3 ARION trial: Evaluating domvanalimab + zimberelimab vs. pembrolizumab in first-line NSCLC
- Phase 2 STAR-121 trial: Gastric cancer in combination with chemotherapy
- Mechanism: Fc-enabled anti-TIGIT for enhanced effector function
Etrumadenant (Adenosine Receptor Antagonist)
- Phase 2 ARC-6 trial: Renal cell carcinoma
- Combination: With zimberelimab and chemotherapy
- Biomarker: CD73 expression as predictive marker
Financial Highlights
- Pre-acquisition market cap: Approximately $12 billion USD
- Key investors: OrbiMed, Vivo Capital, Google Ventures (GV), Casdin Capital
- Cash position at acquisition: Approximately $1.7 billion USD
Neurological Relevance
While primarily focused on immuno-oncology, Arcus's adenosine receptor antagonists may have implications for neuroinflammation in brain tumors and potential CNS applications[@cd]:
- Brain tumor immunotherapy: CD73 and adenosine pathway inhibition in glioblastoma
- CNS inflammation: Potential applications in autoimmune encephalitis
- Blood-brain barrier: Research on CNS penetration of immunotherapies
- [Immunotherapy](/therapeutics/immunotherapy)
- Tumor Microenvironment
- [Adenosine Signaling](/genes/gnal)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Gilead Sciences](/companies/gilead)
- [TIGIT Signaling](/genes/gnal)
- CD73
- Glioblastoma
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/genes/ar)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Arcus Biosciences, Company Website (n.d.)
Arcus Pipeline Overview, Corporate Presentation (n.d.)
Domvanalimab Clinical Trials, ClinicalTrials.gov (n.d.)
Gilead to Acquire Arcus, Press Release (n.d.)
[Adenosine Pathway in Cancer, Nature Reviews Cancer (n.d.)](https://doi.org/10.1038/s41568-019-0196-7)
[TIGIT in Cancer Immunotherapy, Cancer Cell (2020)](https://doi.org/10.1016/j.ccell.2020.07.013)
[CD73 in Glioblastoma, Neuro-Oncology (n.d.)](https://doi.org/10.1093/neuonc/noab123)Pathway Diagram
The following diagram shows the key molecular relationships involving Arcus Biosciences discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)